• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

2 型糖尿病合并与不合并肥胖症患者的医疗结果。

Healthcare outcomes for patients with type 2 diabetes with and without comorbid obesity.

机构信息

Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46225, United States of America.

HealthMetrics Outcomes Research, 27576 River Reach Drive, Bonita Springs, FL 34134, United States of America.

出版信息

J Diabetes Complications. 2020 Dec;34(12):107730. doi: 10.1016/j.jdiacomp.2020.107730. Epub 2020 Sep 5.

DOI:10.1016/j.jdiacomp.2020.107730
PMID:32943301
Abstract

AIMS

Examine the burden of comorbid obesity associated with type 2 diabetes (T2D).

METHODS

The IBM® MarketScan® Explorys Claims Electronic Medical Records Data were used to identify adults with T2D, two recorded body mass index (BMI) values, and continuous insurance coverage from 1 year prior through 1 year post index date. Patients with index BMI ≥18 kg/m and <30 kg/m (normal/overweight) were matched to patients with index BMI ≥ 30 kg/m (obese) using propensity score matching (PSM). Using the PSM cohort, multivariable analyses examined the association between obesity and patient comorbidities, healthcare costs, and resource utilization.

RESULTS

In the matched cohort (16,006 normal/overweight; 16,006 obese), multivariable analyses showed that obesity, compared to normal/overweight, was associated with increased odds of a diabetes-related comorbidity (Odds Ratio [OR] = 1.29; 95% Confidence Interval [CI] 1.21-1.38) and an obesity-related comorbidity (OR = 1.42; 95% CI 1.29-1.56). Obesity was also associated with significantly higher annual diabetes-related and all-cause total costs and resource utilization.

CONCLUSIONS

This research increases the knowledge of how patients with T2D and obesity should be of greater concern for healthcare providers compared to T2D patients without comorbid obesity, given their worse comorbidity profile, increased resource utilization, and higher healthcare costs.

摘要

目的

探讨与 2 型糖尿病(T2D)相关的合并肥胖症的负担。

方法

使用 IBM® MarketScan®Explorys 索赔电子病历数据,确定 T2D 患者,记录两次体重指数(BMI)值,并在指数日期前 1 年至后 1 年期间连续投保。BMI 指数≥18kg/m 和<30kg/m(正常/超重)的患者与 BMI 指数≥30kg/m(肥胖)的患者使用倾向评分匹配(PSM)进行匹配。使用 PSM 队列,多变量分析考察了肥胖症与患者合并症、医疗保健成本和资源利用之间的关联。

结果

在匹配队列(16006 例正常/超重;16006 例肥胖)中,多变量分析显示,与正常/超重相比,肥胖与糖尿病相关合并症(优势比 [OR] = 1.29;95%置信区间 [CI] 1.21-1.38)和肥胖相关合并症(OR = 1.42;95%CI 1.29-1.56)的发生几率增加。肥胖症还与糖尿病相关和所有原因的年度总费用和资源利用率显著增加相关。

结论

与无肥胖合并症的 T2D 患者相比,该研究增加了关于肥胖合并 T2D 患者的知识,因为这些患者的合并症谱更差、资源利用率更高、医疗保健成本更高,因此应引起医疗保健提供者的更大关注。

相似文献

1
Healthcare outcomes for patients with type 2 diabetes with and without comorbid obesity.2 型糖尿病合并与不合并肥胖症患者的医疗结果。
J Diabetes Complications. 2020 Dec;34(12):107730. doi: 10.1016/j.jdiacomp.2020.107730. Epub 2020 Sep 5.
2
The Economic Burden of Obesity by Glycemic Stage in the United States.美国不同血糖阶段肥胖症的经济负担
Pharmacoeconomics. 2015 Jul;33(7):735-48. doi: 10.1007/s40273-014-0248-5.
3
Body mass index and insulin use as identifiers of high-cost patients with type 2 diabetes: A retrospective analysis of electronic health records linked to insurance claims data.体重指数和胰岛素使用作为 2 型糖尿病高费用患者的识别标志:一项基于电子健康记录与保险理赔数据关联的回顾性分析。
Diabetes Obes Metab. 2019 Jun;21(6):1419-1428. doi: 10.1111/dom.13671. Epub 2019 Mar 27.
4
Fracture risk and healthcare resource utilization and costs among osteoporosis patients with type 2 diabetes mellitus and without diabetes mellitus in Japan: retrospective analysis of a hospital claims database.日本2型糖尿病合并和未合并糖尿病的骨质疏松症患者的骨折风险、医疗资源利用及成本:医院理赔数据库的回顾性分析
BMC Musculoskelet Disord. 2016 Nov 25;17(1):489. doi: 10.1186/s12891-016-1344-9.
5
Matched Comparison Examining the Effect of Obesity on Clinical, Economic, and Humanistic Outcomes in Patients with Bipolar I Disorder.匹配对照研究肥胖症对双相 I 障碍患者临床、经济和人文结局的影响。
Adv Ther. 2024 Oct;41(10):3807-3819. doi: 10.1007/s12325-024-02953-3. Epub 2024 Aug 8.
6
Association of obesity with healthcare resource utilization and costs in a commercial population.商业人群中肥胖与医疗资源利用及成本的关联
Curr Med Res Opin. 2018 Jul;34(7):1335-1343. doi: 10.1080/03007995.2018.1464435. Epub 2018 May 10.
7
Obesity and glycemic control among people with type 2 diabetes in the United States: A retrospective cohort study using insurance claims data.美国2型糖尿病患者的肥胖与血糖控制:一项使用保险理赔数据的回顾性队列研究。
J Diabetes Complications. 2021 Sep;35(9):107975. doi: 10.1016/j.jdiacomp.2021.107975. Epub 2021 Jun 19.
8
Incremental burden of comorbid major depressive disorder in patients with type 2 diabetes or cardiovascular disease: a retrospective claims analysis.2 型糖尿病或心血管疾病患者合并重度抑郁障碍的增量负担:一项回顾性理赔分析。
BMC Health Serv Res. 2021 Aug 6;21(1):778. doi: 10.1186/s12913-021-06802-9.
9
Real-World Claims Analyses of Comorbidity Burden, Treatment Pattern, Healthcare Resource Utilization, and Costs in Pediatric Psoriasis.儿童银屑病合并症负担、治疗模式、医疗资源利用及成本的真实世界索赔分析
Adv Ther. 2021 Jul;38(7):3948-3961. doi: 10.1007/s12325-021-01795-7. Epub 2021 Jun 6.
10
Are healthcare costs from obesity associated with body mass index, comorbidity or depression? Cohort study using electronic health records.肥胖导致的医疗费用与体重指数、合并症或抑郁症有关吗?一项使用电子健康记录的队列研究。
Clin Obes. 2016 Jun;6(3):225-31. doi: 10.1111/cob.12144. Epub 2016 Apr 21.

引用本文的文献

1
Mobile Health Interventions for Individuals with Type 2 Diabetes and Overweight or Obesity-A Systematic Review and Meta-Analysis.2型糖尿病合并超重或肥胖个体的移动健康干预措施——一项系统评价与Meta分析
J Funct Morphol Kinesiol. 2025 Jul 29;10(3):292. doi: 10.3390/jfmk10030292.
2
Real-world use and effectiveness of tirzepatide among individuals without type 2 diabetes: Results from the Optum Market Clarity database.替尔泊肽在非2型糖尿病个体中的真实世界应用及有效性:来自Optum市场洞察数据库的结果
Diabetes Obes Metab. 2025 May;27(5):2810-2821. doi: 10.1111/dom.16290. Epub 2025 Feb 25.
3
Prevalence of complications and comorbidities associated with obesity: a health insurance claims analysis.
肥胖相关并发症和合并症的患病率:一项医疗保险理赔分析。
BMC Public Health. 2025 Jan 22;25(1):273. doi: 10.1186/s12889-024-21061-z.
4
Applying machine learning approaches for predicting obesity risk using US health administrative claims database.应用机器学习方法,利用美国健康管理数据库预测肥胖风险。
BMJ Open Diabetes Res Care. 2024 Sep 26;12(5):e004193. doi: 10.1136/bmjdrc-2024-004193.
5
Glucagon-Like Peptide-1 Receptor Agonists Do Not Increase Aspiration During Upper Endoscopy in Patients With Diabetes.胰高血糖素样肽-1受体激动剂不会增加糖尿病患者上消化道内镜检查期间的误吸风险。
Clin Gastroenterol Hepatol. 2025 Apr;23(5):739-747. doi: 10.1016/j.cgh.2024.04.038. Epub 2024 May 15.
6
Oral glucagon-like peptide-1 receptor agonists and combinations of entero-pancreatic hormones as treatments for adults with type 2 diabetes: where are we now?口服胰高血糖素样肽-1 受体激动剂和肠促胰岛素联合治疗成人 2 型糖尿病:我们现在在哪里?
Expert Opin Pharmacother. 2024 May;25(7):801-818. doi: 10.1080/14656566.2024.2356254. Epub 2024 May 22.
7
The Association Between Obesity and the 5-Year Prevalence of Morbidity and Mortality Among Adults with Type 2 Diabetes.肥胖与2型糖尿病成人患者5年发病率和死亡率患病率之间的关联。
Diabetes Ther. 2023 Apr;14(4):709-721. doi: 10.1007/s13300-023-01384-7. Epub 2023 Feb 23.
8
The factors associated with orthorexia nervosa in type 2 diabetes and their effect on diabetes self-management scores.与 2 型糖尿病相关的饮食失调症(强迫性正常饮食)的因素及其对糖尿病自我管理评分的影响。
Eat Weight Disord. 2023 Feb 21;28(1):22. doi: 10.1007/s40519-023-01552-5.
9
Prehabilitation of overweight and obese patients with dysglycemia awaiting bariatric surgery: Predicting the success of obesity treatment.等待减重手术的血糖异常超重和肥胖患者的术前康复:预测肥胖治疗的成功率。
World J Diabetes. 2022 Dec 15;13(12):1096-1105. doi: 10.4239/wjd.v13.i12.1096.
10
Factors associated with treatment adherence to treatment among in patients with type 2 diabetes in Iran: A cross-sectional study.伊朗 2 型糖尿病住院患者治疗依从性相关因素的横断面研究。
Front Public Health. 2022 Nov 1;10:976888. doi: 10.3389/fpubh.2022.976888. eCollection 2022.